Investing.com – Shares of Ondine (LSE: OND ) fell 4.2% today, despite the company reporting that its partner HCA Healthcare (NYSE 🙂 has invested $4 million in new capital into the company.
The price is 8.5p/share, which is the same price as in November 2024. According to RBC, the investment will expand the company’s cash flow through Q4 2025.
RBC analysts commented on the situation, stating: “While Ondine has already indicated that it has spoken to a ‘major US healthcare group’, which we assumed to be HCA, this is clearly positive news for Ondine, in our view. Not only.” Does strengthen the balance sheet, but provides further evidence in HCA’s buyout of Steriwave, which is currently in Phase 3 clinical trials at its hospitals, expected to end in mid-2025. “.
On the other hand, the company also announced a delay in receiving US$5 million (approximately £2.8 million) from a Canadian private equity investor. However, Ondine remains optimistic about completing the position.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
